Receptor-Interacting Protein Serine-Threonine Kinase 2
"Receptor-Interacting Protein Serine-Threonine Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A RIP serine-theonine kinase that contains a C-terminal caspase activation and recruitment domain. It can signal by associating with other CARD-signaling adaptor proteins and INITIATOR CASPASES that contain CARD domains within their N-terminal pro-domain region.
MeSH Number(s)
D08.811.913.696.620.682.700.801.500
D12.644.360.024.131.750
D12.644.360.024.500.186.500
D12.644.360.075.358.750
D12.776.157.057.004.750
D12.776.157.057.500.186.500
D12.776.476.024.139.750
D12.776.476.024.500.186.500
D12.776.476.075.358.750
Concept/Terms
Receptor-Interacting Protein Serine-Threonine Kinase 2- Receptor-Interacting Protein Serine-Threonine Kinase 2
- Receptor Interacting Protein Serine Threonine Kinase 2
- CARDIAK
- RICK Protein
- RIPK2 Protein
- CARD-containing Interleukin (IL)-1 beta Converting Enzyme
- Receptor-Interacting Serine-Threonine Kinase 2
- Receptor Interacting Serine Threonine Kinase 2
Below are MeSH descriptors whose meaning is more general than "Receptor-Interacting Protein Serine-Threonine Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Receptor-Interacting Protein Serine-Threonine Kinase 2".
This graph shows the total number of publications written about "Receptor-Interacting Protein Serine-Threonine Kinase 2" by people in Harvard Catalyst Profiles by year, and whether "Receptor-Interacting Protein Serine-Threonine Kinase 2" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
Below are the most recent publications written about "Receptor-Interacting Protein Serine-Threonine Kinase 2" by people in Profiles.
-
Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-?B pathway. Cancer Lett. 2022 04 01; 530:59-67.
-
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2021 11 01; 321(5):G500-G512.
-
MicroRNA-146a limits tumorigenic inflammation in colorectal cancer. Nat Commun. 2021 04 23; 12(1):2419.
-
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 07 25; 62(14):6482-6494.
-
A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 03 26; 116(13):6435-6440.
-
Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019 03 06; 10(3):226.
-
The NOD2 signaling in peripheral macrophages contributes to neuropathic pain development. Pain. 2019 Jan; 160(1):102-116.
-
MicroRNA-135a Modulates Hepatitis C Virus Genome Replication through Downregulation of Host Antiviral Factors. Virol Sin. 2019 Apr; 34(2):197-210.
-
Computational design of new protein kinase 2 inhibitors for the treatment of inflammatory diseases using QSAR, pharmacophore-structure-based virtual screening, and molecular dynamics. J Mol Model. 2018 Aug 07; 24(9):225.
-
Frontline Science: RIP2 promotes house dust mite-induced allergic airway inflammation. J Leukoc Biol. 2018 09; 104(3):447-459.